Compare OMEX & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | IMMP |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 54.4M |
| IPO Year | 2024 | 2012 |
| Metric | OMEX | IMMP |
|---|---|---|
| Price | $0.90 | $0.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 678.9K | 605.0K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,327.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $0.29 |
| 52 Week High | $4.43 | $3.53 |
| Indicator | OMEX | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 38.68 |
| Support Level | $0.87 | $0.35 |
| Resistance Level | $1.72 | $0.39 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 6.16 | 29.98 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. It discovers, validates, and develops high-value seafloor mineral resources and provides specialized mineral exploration, project development, and marine services to its clients. The company's subsea project portfolio contains multiple projects in various stages of development, such as the Phosagmex Project, a rich deposit of phosphate sands located seventy-ninety meters deep within the Mexican EEZ; two polymetallic nodule exploration license holders in the Cook Islands' EEZ; the Lihir Gold Project, a subsea area that contains several prospective gold exploration targets located in the Papua New Guinea Exclusive Economic Zone (EEZ); and others.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.